These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 8167090

  • 21. [Palliative treatment of bone metastases with bone-seeking radionuclides].
    De Klerk JM, Zonnenberg BA, Huiskes AW, Han SH, Blijham GH, Van Rijk PP.
    Ned Tijdschr Geneeskd; 1998 Nov 28; 142(48):2618-22. PubMed ID: 10028362
    [Abstract] [Full Text] [Related]

  • 22. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA.
    Urology; 1997 Nov 28; 50(5):747-53. PubMed ID: 9372886
    [Abstract] [Full Text] [Related]

  • 23. Strontium and samarium therapy for bone metastases from prostate carcinoma.
    Dickie GJ, Macfarlane D.
    Australas Radiol; 1999 Nov 28; 43(4):476-9. PubMed ID: 10901963
    [Abstract] [Full Text] [Related]

  • 24. Hypocalcemia associated with strontium-89 administration in a patient with diffuse bone metastases from neuroendocrine carcinoma.
    Mori M, Fadul NA, Bruera E, Dalal S.
    J Pain Symptom Manage; 2009 May 28; 37(5):923-9. PubMed ID: 19041217
    [Abstract] [Full Text] [Related]

  • 25. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy.
    Kurosaka S, Satoh T, Chow E, Asano Y, Tabata K, Kimura M, Tsumura H, Matsumoto K, Ishiyama H, Inoue Y, Hayakawa K, Baba S.
    Ann Nucl Med; 2012 Jul 28; 26(6):485-91. PubMed ID: 22477263
    [Abstract] [Full Text] [Related]

  • 26. [Internal strontium-89 radiotherapy for malignant bony metastasis].
    Lou C, Zhang D, Yu L.
    Zhonghua Zhong Liu Za Zhi; 2001 Nov 28; 23(6):507-9. PubMed ID: 11859724
    [Abstract] [Full Text] [Related]

  • 27. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 28; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 28. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ.
    J Nucl Med; 1997 Aug 28; 38(8):1175-9. PubMed ID: 9255144
    [Abstract] [Full Text] [Related]

  • 29. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF, Guhlke S, Biersack HJ.
    J Clin Oncol; 2003 Aug 01; 21(15):2869-75. PubMed ID: 12885803
    [Abstract] [Full Text] [Related]

  • 30. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D, Yardley J.
    Semin Oncol; 1993 Jun 01; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [Abstract] [Full Text] [Related]

  • 31. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N.
    J Nucl Med; 1999 Feb 01; 40(2):256-61. PubMed ID: 10025832
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases.
    Baczyk M, Milecki P, Pisarek M, Gut P, Antczak A, Hrab M.
    Neoplasma; 2013 Feb 01; 60(3):328-33. PubMed ID: 23374004
    [Abstract] [Full Text] [Related]

  • 35. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy.
    Leong C, McKenzie MR, Coupland DB, Gascoyne RD.
    J Nucl Med; 1994 Oct 01; 35(10):1662-4. PubMed ID: 7931669
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
    Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE.
    Int J Radiat Oncol Biol Phys; 1993 Apr 02; 25(5):805-13. PubMed ID: 8478230
    [Abstract] [Full Text] [Related]

  • 40. [Nuclear medicine therapy of bone metastases].
    Kimmig B, Hermann HJ, Kober B.
    Rontgenblatter; 1983 Jul 02; 36(7):216-9. PubMed ID: 6622951
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.